CaSR’s positive allostericmodulators (PAM) (e.g., cinacalcet and etelcalcetide) are FDA-approveddrugs to treat patients with secondary hyperparathyroidism.11,12 CaSR’s negative allosteric modulators (NAM), such as NPS2143,were evaluated for osteoporosis and are emerging therapeutics forasthma.7,13,14 Therefore,CaSR plays multifunctional roles in human physiology and pathology. This evidence concerns the gene CASR and secondary hyperparathyroidism.